Gut Microbiota and Intestinal Permeability Responses to Ramadan Intermittent Fasting in Italian and Lebanese Cohorts: a Real-life Study
1 other identifier
observational
79
1 country
1
Brief Summary
Ramadan Intermittent Fasting (RIF) is an annual fasting month from dawn to sunset, practiced by healthy Muslims. While its metabolic benefits are well studied, its effects on the gastrointestinal (GI) tract, intestinal permeability, and GI microbiota remain less explored. This study investigated the effects of RIF on gut microbiota composition and markers of intestinal permeability in two distinct populations, i.e., Italy and Lebanon. Participants from Italy and Lebanon were enrolled in this observational longitudinal study and were monitored before, during, and after RIF. Dietary intake was assessed through a validated 3-day food questionnaire before and during RIF. Blood and fecal samples were collected to analyze the markers of intestinal permeability (zonulin, lipopolysaccharide (LPS), Fatty Acid Binding Protein 2 (FABP2), and total bile acids (TBA), and gut microbiota composition using the 16S rRNA gene sequencing.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2024
CompletedFirst Submitted
Initial submission to the registry
May 12, 2026
CompletedFirst Posted
Study publicly available on registry
May 19, 2026
CompletedJune 16, 2026
June 1, 2026
29 days
May 12, 2026
June 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in Intestinal Permeability Markers
Zonulin and LPS levels were measured through ELISA experiments where blood serum was collected from patients before and after the ending of the fasting month.
One month
Secondary Outcomes (1)
Effect of RIF on Gut Microbiota Composition
1 month
Study Arms (2)
Italian group
Muslims in Italy
Lebanese Group
Muslims in Lebanon
Eligibility Criteria
should be muslims in which they are able to do one month of fasting without complications
You may qualify if:
- subjects able to provide signed consent
- age between 20-60 years
- Healthy Volunteers
You may not qualify if:
- Lack of informed consent
- pregnancy
- celiac disease
- diagnosis of organic diseases, cardiovascular risk
- medications that can affect the gastrointestinal tract and interfere with symptoms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J - Clinica medica "A. Murri"
Bari, BA, 70124, Italy
Related Publications (2)
Khalil M, Abdallah H, Jaber N, Garruti G, Di Ciaula A, Portincasa P. Distinct biophysiological effects of Ramadan fasting and traditional intermittent fasting on markers of body fat storage. A real-life study. Eur J Intern Med. 2024 Nov;129:111-120. doi: 10.1016/j.ejim.2024.08.014. Epub 2024 Aug 26.
PMID: 39191620BACKGROUNDAbdallah H, Khalil M, Farella I, JohnBritto JS, Lanza E, Santoro S, Garruti G, Portincasa P, Di Ciaula A, Bonfrate L. Ramadan intermittent fasting reduces visceral fat and improves gastrointestinal motility. Eur J Clin Invest. 2023 Sep;53(9):e14029. doi: 10.1111/eci.14029. Epub 2023 May 19.
PMID: 37203871BACKGROUND
Biospecimen
blood samples were collected for intestinal permeability analysis
Study Officials
- PRINCIPAL INVESTIGATOR
Piero Portincasa
Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J) University of Bari 'Aldo Moro'
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Month
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Piero Portincasa , MD, PhD, Dr honoris. Causa ., AGAF Professor of internal medicine Chief, Clinica Medica "A. Murri" Director, Dept. Biomedical Sciences & Human Oncology
Study Record Dates
First Submitted
May 12, 2026
First Posted
May 19, 2026
Study Start
March 11, 2024
Primary Completion
April 9, 2024
Study Completion
May 1, 2024
Last Updated
June 16, 2026
Record last verified: 2026-06